BMS misses a beat in cancer comeback
Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. The therapy had been a key part of BMS's strategy for a comeback in cancer therapies. Feedback from the FDA prompted the reversal. BMS is expected to seek approval soon for the melanoma drug ipilimumab, which is being developed in partnership with Medarex.
- here's the report
- and here's an article from Scientific American on BMS' cancer efforts
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets